{"id":{"repo_id":"birmingham","oai_identifier":"oai:etheses.bham.ac.uk:10546"},"canonical_url":"https://search.ndltd.org/etd/birmingham/oai:etheses.bham.ac.uk:10546","repository":{"repo_id":"birmingham","name":"University of Birmingham","base_url":"https://etheses.bham.ac.uk/cgi/oai2"},"display":{"title":"Evaluation of prophylactic therapies for the prevention of campylobacteriosis","abstract":"Campylobacter jejuni, a frequently isolated diarrhoeal pathogen [1], is encapsulated by a polysaccharide capsule. This can be exploited to develop capsule-based conjugate vaccines [2]. Before vaccine implementation, correlates of protection enable efficacy to be measured. This thesis describes the development of a Serum Bactericidal Assay (SBA) to evaluate the bactericidal activity of sera from New Zealand White Rabbits (NZWR) vaccinated with a GMP grade capsule-based conjugate C. jejuni vaccine ‘CJCV1’; Aotus nancymaae Non-Human Primates (NHP), vaccinated with a research grade vaccine ‘CCV’; and humans, vaccinated with ‘CJCV1’. NZWR and NHP post-vaccination sera demonstrated an increase in serum titre achieving a bactericidal effect. Human sera did not demonstrate a consistent bactericidal effect. These experiments showed variability in readouts, suggesting that for the studies performed, the SBA may be of limited value in assessing vaccine efficacy. This thesis also presents results from a Phase II clinical trial assessing the efficacy of rifaximin in preventing campylobacteriosis in humans; whilst rifaximin prophylaxis does not prevent campylobacteriosis, it reduces the diarrhoeal burden. This study involved the development and use of a successful human challenge model, crucial for testing interventions against campylobacteriosis. Results from these studies suggest further development of interventions to control this highly problematic pathogen are required.","abstract_html":"Campylobacter jejuni, a frequently isolated diarrhoeal pathogen [1], is encapsulated by a polysaccharide capsule. This can be exploited to develop capsule-based conjugate vaccines [2]. Before vaccine implementation, correlates of protection enable efficacy to be measured. This thesis describes the development of a Serum Bactericidal Assay (SBA) to evaluate the bactericidal activity of sera from New Zealand White Rabbits (NZWR) vaccinated with a GMP grade capsule-based conjugate C. jejuni vaccine ‘CJCV1’; Aotus nancymaae Non-Human Primates (NHP), vaccinated with a research grade vaccine ‘CCV’; and humans, vaccinated with ‘CJCV1’. NZWR and NHP post-vaccination sera demonstrated an increase in serum titre achieving a bactericidal effect. Human sera did not demonstrate a consistent bactericidal effect. These experiments showed variability in readouts, suggesting that for the studies performed, the SBA may be of limited value in assessing vaccine efficacy. This thesis also presents results from a Phase II clinical trial assessing the efficacy of rifaximin in preventing campylobacteriosis in humans; whilst rifaximin prophylaxis does not prevent campylobacteriosis, it reduces the diarrhoeal burden. This study involved the development and use of a successful human challenge model, crucial for testing interventions against campylobacteriosis. Results from these studies suggest further development of interventions to control this highly problematic pathogen are required.","abstract_has_math":false,"creators":["Rimmer, Joanna Elizabeth"],"institution":"University of Birmingham","degree_name":"d_m_d","degree_level":"d_m_d","degree_discipline":null,"degree_department":null,"school":null,"contributors":[],"advisors":[],"committee_chairs":[],"committee_members":[],"year":2020,"date_issued":"2020-07","date_published":"2020-07","updated_at":"2026-11-19T09:31:12Z","subjects":[],"languages":["eng"],"rights":[],"rights_urls":[],"identifier_entries":[],"person_identifier_entries":[]},"links":{"outbound_url":null,"outbound_label":null,"outbound_source":null,"record_url":null,"record_label":null,"record_kind":null,"record_source":null,"download_url":"http://etheses.bham.ac.uk//id/eprint/10546/7/Rimmer2020MD.pdf","download_label":"Download PDF","download_source":"dc:identifier.uri","access_status":null,"embargo_until":null,"access_note":null},"source_record":{"url":"https://etheses.bham.ac.uk/cgi/oai2?verb=GetRecord&metadataPrefix=uketd_dc&identifier=oai%3Aetheses.bham.ac.uk%3A10546","prefix":"uketd_dc"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:contributor.sponsor","label":"Sponsor","values":["na"]},{"key":"dc:creator","label":"Author","values":["Rimmer, Joanna Elizabeth"]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date","label":"Dc Date","values":["2020-07"]},{"key":"dc:date.issued","label":"Date","values":["2020-07"]},{"key":"dc:publisher.department","label":"Dc Publisher Department","values":["College of Medical & Dental Sciences","School of Immunity and Infection"]},{"key":"dc:publisher.institution","label":"Dc Publisher Institution","values":["University of Birmingham"]},{"key":"dc:relation.isreferencedby","label":"Dc Relation Isreferencedby","values":["http://etheses.bham.ac.uk//id/eprint/10546/"]},{"key":"dc:type","label":"Dc Type","values":["Thesis"]},{"key":"dc:type.qualificationlevel","label":"Dc Type Qualificationlevel","values":["d_m_d"]},{"key":"dc:type.qualificationname","label":"Dc Type Qualificationname","values":["d_m_d"]}]},{"id":"language_rights","label":"Language and Rights","entries":[{"key":"dc:language.dcterms_iso639_2","label":"Language (ISO 639-2)","values":["eng"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier.uri","label":"Identifier URI","values":["http://etheses.bham.ac.uk//id/eprint/10546/7/Rimmer2020MD.pdf"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description.abstract","label":"Abstract","values":["Campylobacter jejuni, a frequently isolated diarrhoeal pathogen [1], is encapsulated by a polysaccharide capsule. This can be exploited to develop capsule-based conjugate vaccines [2]. Before vaccine implementation, correlates of protection enable efficacy to be measured. This thesis describes the development of a Serum Bactericidal Assay (SBA) to evaluate the bactericidal activity of sera from New Zealand White Rabbits (NZWR) vaccinated with a GMP grade capsule-based conjugate C. jejuni vaccine ‘CJCV1’; Aotus nancymaae Non-Human Primates (NHP), vaccinated with a research grade vaccine ‘CCV’; and humans, vaccinated with ‘CJCV1’. NZWR and NHP post-vaccination sera demonstrated an increase in serum titre achieving a bactericidal effect. Human sera did not demonstrate a consistent bactericidal effect. These experiments showed variability in readouts, suggesting that for the studies performed, the SBA may be of limited value in assessing vaccine efficacy. This thesis also presents results from a Phase II clinical trial assessing the efficacy of rifaximin in preventing campylobacteriosis in humans; whilst rifaximin prophylaxis does not prevent campylobacteriosis, it reduces the diarrhoeal burden. This study involved the development and use of a successful human challenge model, crucial for testing interventions against campylobacteriosis. Results from these studies suggest further development of interventions to control this highly problematic pathogen are required."]},{"key":"dc:format","label":"Dc Format","values":["text"]},{"key":"dcterms:accessrights","label":"Dcterms Accessrights","values":["public"]},{"key":"dc:title","label":"Title","values":["Evaluation of prophylactic therapies for the prevention of campylobacteriosis"]}]}],"canonical_facts":{"dc:contributor.sponsor":["na"],"dc:creator":["Rimmer, Joanna Elizabeth"],"dc:date":["2020-07"],"dc:date.issued":["2020-07"],"dc:description.abstract":["Campylobacter jejuni, a frequently isolated diarrhoeal pathogen [1], is encapsulated by a polysaccharide capsule. This can be exploited to develop capsule-based conjugate vaccines [2]. Before vaccine implementation, correlates of protection enable efficacy to be measured. This thesis describes the development of a Serum Bactericidal Assay (SBA) to evaluate the bactericidal activity of sera from New Zealand White Rabbits (NZWR) vaccinated with a GMP grade capsule-based conjugate C. jejuni vaccine ‘CJCV1’; Aotus nancymaae Non-Human Primates (NHP), vaccinated with a research grade vaccine ‘CCV’; and humans, vaccinated with ‘CJCV1’. NZWR and NHP post-vaccination sera demonstrated an increase in serum titre achieving a bactericidal effect. Human sera did not demonstrate a consistent bactericidal effect. These experiments showed variability in readouts, suggesting that for the studies performed, the SBA may be of limited value in assessing vaccine efficacy. This thesis also presents results from a Phase II clinical trial assessing the efficacy of rifaximin in preventing campylobacteriosis in humans; whilst rifaximin prophylaxis does not prevent campylobacteriosis, it reduces the diarrhoeal burden. This study involved the development and use of a successful human challenge model, crucial for testing interventions against campylobacteriosis. Results from these studies suggest further development of interventions to control this highly problematic pathogen are required."],"dc:format":["text"],"dc:identifier.uri":["http://etheses.bham.ac.uk//id/eprint/10546/7/Rimmer2020MD.pdf"],"dc:language.dcterms_iso639_2":["eng"],"dc:publisher.department":["College of Medical & Dental Sciences","School of Immunity and Infection"],"dc:publisher.institution":["University of Birmingham"],"dc:relation.isreferencedby":["http://etheses.bham.ac.uk//id/eprint/10546/"],"dcterms:accessrights":["public"],"dc:title":["Evaluation of prophylactic therapies for the prevention of campylobacteriosis"],"dc:type":["Thesis"],"dc:type.qualificationlevel":["d_m_d"],"dc:type.qualificationname":["d_m_d"]},"updated_at":"2026-11-19T09:31:12Z"}